|Bid||79.37 x 900|
|Ask||79.43 x 1400|
|Day's range||78.95 - 81.74|
|52-week range||66.89 - 164.86|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||188.86|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||99.79|
The Nasdaq is down 27% this year, and that can be incredibly discouraging for growth investors. The moral of the story is that long-term investors should not ignore the Nasdaq. Three Nasdaq-based stocks that are full of potential today are DexCom (NASDAQ: DXCM), Meta Platforms (NASDAQ: META), and Comcast (NASDAQ: CMCSA).
Bear markets are never fun. Keeping with this theme, the 2022 bear market has created a slew of attractive buying opportunities. Cosmetic surgery company InMode (NASDAQ: INMD), Swiss pharma giant Novartis (NYSE: NVS), and diabetes care behemoth DexCom (NASDAQ: DXCM) are three highly profitable companies that have been unfairly punished by this irrational market.
Diabetes company DexCom (NASDAQ: DXCM) has been an incredible investment over the past decade. Is DexCom's stock too expensive, or is this an investment that still has enough runway left to potentially help you become a millionaire? DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes stay on top of their glucose levels.